CYDY News and Press, CytoDyn Inc From 08/26/21

Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent ...

Company Has Sought to Block Stockholders’ Right to Vote for Group’s Highly Qualified Nominees A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experien...

3 Penny Stocks on Robinhood to Watch As August Ends Robinhood is one of the most popular platforms to find penny stocks right now. But before we go any further, it’s worth discussing what penny stocks are. A penny stock is any stock trading under $5 per share. And as a re...

Shareholders Using the Group’s Proxy Card Risk Not Having Their Votes Counted at Annual Meeting Federal Court Grants CytoDyn’s Motion for Expedited Discovery from the Rosenbaum/Patterson Group Shareholders Do Not Need to Take Any Action at this Time ...

Decreases in Circulating Tumor Cells after leronlimab induction were seen in 73% of the patients and associated with increase in PFS and OS CytoDyn plans to update its Breakthrough Therapy designation application and file for BTD for mTNBC VANCOUVER, Washington, Aug. 25, 2...

3 Biotech Penny Stocks For Your September Watchlist Are biotech penny stocks worth buying? This is a question that many penny stocks investors wonder about, and the answer is quite clear. Depending on what type of trader you are and what your tolerance for volatility is, biotech p...

CYDY CEO Desperately Seeking to Protect Outsized Pay Package Despite Repeated Failures A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experienced...

CytoDyn has a single asset - leronlimab - which it is running through trials in nearly every major disease known to man. The stock has seen huge movement after the company started with covid-19. If the company manages to file its HIV BLA, the stock could shoot up. For furthe...

Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission CMC and Non-Clinical Sections Will Be Fully Resubmitted as Early as September 2021 VANCOUVER, Washington, Aug. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“Cyto...

CytoDyn (OTCQB:CYDY) has filed a lawsuit against a shareholder activist group led by Paul Rosenbaum and Bruce Patterson, accusing them of misleading shareholders and waging an unlawful proxy contest. The lawsuit was filed in the United States District Court for the District of Delaware. "We a...